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Background: Neurofibromatosis type 1 (NF1) is a multi-systemic disease caused by neurofibromin deficiency. The
reduced life expectancy of patients with NF1 has been attributed to NF1-associated malignant neoplasms. However,
an analysis of death certificates in the USA suggests that vascular disease could be an important cause of early
death among these patients. Endothelial dysfunction (ED) is related to vasculopathy and is an early marker of
subclinical atherosclerosis. Since neurofibromin has already been demonstrated to affect endothelial cell function,
ED may be associated with NF1. The purpose of this study was to assess endothelial function in patients with NF1
using a non-invasive method.
Methods: NF1 patients and healthy control subjects, aged 18 to 35 years, were included. Subjects were excluded if
they had any risk factor for vascular disease or any other condition known to affect endothelial function. Endothelial
function was assessed using reactive hyperemia-peripheral arterial tone (RH-PAT) technology. ED was defined as a
reactive hyperemia index (RHI) lower than 1.35.
Results: Four of the 29 (13.8%) NF1 patients and 1 of the 30 (3.3%) healthy volunteers had ED (p = 0.153). RHI
medians and interquartile intervals were 1.8 (1.58-2.43) for the NF1 group and 2.02 (1.74 – 2.49) for the control
group (p = 0.361).
Conclusion: The prevalence of ED was similar in NF1 patients and healthy controls.
Keywords: Neurofibromatosis type 1, Endothelial dysfunction, Peripheral arterial tonometry, Reactive hyperemiaBackground
Neurofibromatosis type 1 (NF1) is an autosomal domin-
ant genetic disease caused by mutations in the
neurofibromin-encoding gene, located on chromosome
17q11.2. Neurofibromin is a tumor suppressor protein
and NF1 is one of the most common monogenetic dis-
eases, with a prevalence of 1:3,500 to 5,000 [1].
NF1 is a multi-systemic disease that presents with
complete penetrance, but an extremely variable expres-
sivity. The most common clinical features are multiple
café-au-lait spots, dermal and plexiform neurofibromas,
axillary and/or inguinal freckling, Lisch nodes, and cog-
nitive and muscle-skeletal disorders [2]. NF1 has a large
impact on patient quality of life, because of its associated* Correspondence: draluizarodrigues@gmail.com
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reproduction in any medium, provided the ormorbidities, its aesthetic complications, its unpredictable
chronic clinical course, and the possibility of affecting
descendants.
NF1 has been shown to reduce life expectancy by ap-
proximately 15 years [3,4], a reduction attributed to
NF1-associated malignant neoplasms. Surprisingly, how-
ever, a population-based analysis of death certificates in
the USA [3] suggested that vascular disease may be an
important cause of death in younger patients in NF1. In
contrast, a similar study performed 10 years later in an
Italian population [4] found that the rate of vascular
disease-associated deaths in NF1 patients was lower.
Despite this difference and the limitations of death cer-
tificate analyses, these findings were of interest, because
they suggested that vascular disease, a potentially treat-
able or preventable complication, might be a main cause
of early death in individuals with NF1.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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understood [5]. Neurofibromin expression has been
demonstrated in endothelial and smooth muscle vascular
cells in murine models of NF1 [6,7]. Chronic vascular
inflammation observed in humans with NF1 and in mur-
ine models of NF1 [8] may be a cause of endothelial dys-
function (ED).
ED is an early event in the development of atheroscler-
osis. Several risk factors can lead to endothelial activation,
which induces the expression of genes that are normally
suppressed [9]. Changes in vascular morphology are pre-
ceded by ED, which also contributes to atherosclerotic
plaque growth and clinical vascular disease [10].
ED is a systemic process, and there is an established cor-
relation between the coronary and the peripheral vascula-
ture allowing the development of non-invasive techniques
to assess endothelial function. EndoPAT (Itamar Medical,
Israel) equipment is a non-examiner dependent, non-
invasive technology known as “reactive hyperemia periph-
eral arterial tone” (RH-PAT) technology. This system de-
tects pulsatile plethysmographic signals through external
finger probes, which are then digitally recorded and ana-
lyzed with the equipment’s software. This technique, also
called PAT, has been validated for the assessment of endo-
thelial function in patients with peripheral and coronary
atherosclerotic disease (CAD) [11,12].
The present study aimed to non-invasively assess
endothelial function in young adult NF1 patients using
the PAT technology.
Methods
This study was designed as a cross-sectional analysis to
measure the difference in the prevalence of ED between
a group of patients with NF1 and a group of participants
without NF1. The other characteristics of the groups
were similar. The institution’s ethics committee ap-
proved the study.
The sample of participants in the NF1 group was non-
probabilistic and was selected from medical files at the
Neurofibromatosis Outpatient Reference Center
(NORC), by age (ranging from 18 to 35 years old) and
place of residence (to ensure compliance with protocol
visits). The estimated necessary sample size to find a
30% between group difference in the percentage of sub-
jects with ED, with a power of 80% and an alpha error of
5%, was calculated to be 27 (results from OpenEpi, Ver-
sion 2, open source calculator, sample size for cross-
sectional studies).
Patients with NF1 aged 18 to 35 years old and residing
in Belo Horizonte (MG - Brazil) were selected from their
NORC files. All patients were diagnosed clinically, based
on the presence of two or more of the following NIH con-
sensus criteria: six or more café-au-lait spots, 2 or more
ordinary neurofibromas or 1 plexiform neurofibroma,axillary and/or inguinal freckling, optic glioma, 2 or more
Lisch nodules, osseous dysplasia of the sphenoid wing or
tibia, and a first degree relative with NF1. To avoid the in-
clusion of patients with Legius syndrome [13,14], patients
who presented with café-au-lait spots and intertriginous
freckling had to also have a third diagnostic criterion for
NF1. Patients were contacted by telephone. Healthy vol-
unteers were recruited from the area located around the
Federal University of Minas Gerais by personal or e-mail
communication.
NF1 patients were included if they had been diagnosed
with NF1, were aged between 18 and 35 years old and
provided written informed consent. Control volunteers
were included if they were aged between 18 and 35 years
old and provided written informed consent. Both NF1
patients and control volunteers were excluded if they
had any risk factor for CAD, including arterial hyperten-
sion, obesity, family history of early CAD or unknown,
dyslipidemia, diabetes mellitus or glucose intolerance
and smoking; or used any medication affecting endothe-
lial function, including nitrates, alpha- and beta-blockers
, calcium channel blockers, angiotensin converting en-
zyme inhibitors and statins, less than 48 hours prior to
examination.
The height and weight of all were measured; and level
of physical activity, smoking habits and the use of hor-
monal contraceptives were self-reported. Active individ-
uals were defined as those who engaged in more than
1 hour per week of self-defined moderate to high inten-
sity physical activity. Smokers were defined as individ-
uals who had smoked tobacco during the last month. All
smokers were excluded from the analysis.
Endothelial function was tested using EndoPAT
(Itamar Medical). Each participant assumed a dorsal de-
cubitus position with both arms resting relaxed on sup-
ports, in a silent and temperature-controlled (21° to
24°C) environment with low-light, according to the man-
ufacturer’s instructions. Probes were placed on the sec-
ond fingers of both hands. Signals were acquired for 15
minutes, with the first 5 minutes considered baseline,
the next 5 minutes considered the arterial occlusion
period, and the last 5 minutes considered the reactive
hyperemia period. Arterial occlusion was achieved using
an aneroid cuff inflated to 200 mmHg of pressure on the
non-dominant arm.
All volunteers fasted for 3 to 12 hours before the test.
Blood samples were collected and tests of thyroid func-
tion (TSH, FT4), lipid profile (cholesterol and triglycer-
ides), fasting blood glucose, blood count (RBC, WBC
and platelets), liver profile (AST, ALT, bilirubin, pro-
thrombin activity), and kidney function (serum urea,
serum creatinine) were performed. Subjects whose test
results were not within normal ranges were excluded
from the analysis.
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index (RHI), which is automatically calculated by the
EndoPAT software (Figure 1) as the ratio of the average
amplitude of the PAT signal over a 1-minute time inter-
val, starting 1 minute after cuff deflation, divided by the
average amplitude of the PAT signal over a 3.5-minute
time period before cuff inflation (baseline). PAT index
values from the study arm were normalized to those of
the control arm, yielding the RHI final result [12]. RHI
is not a normally distributed variable; therefore, it was
analyzed with non-parametric statistical tests. RHI was
transformed into its natural logarithm (LnRHI), which is
normally distributed, for further analysis with parametric
tests. The significance level was set at 0.05 (p < 0.05).
Independent variables included age, proportion of
women to men, proportion of active to sedentary indi-
viduals, weight, height, body mass index, arterial blood
pressure and resting heart rate.
Since co-variables differently distributed in the two
groups could influence RHI results, a covariance analysis
was performed to adjust for this possibility. All statistical
analyses were performed with IBM SPSS Statistics soft-
ware, version 18.
Results
Twenty-nine NF1 patients and 30 healthy volunteers
were evaluated. Their baseline demographic characteris-
tics were similar, including age, ratio of women to men,
ratio of physically active to inactive participants, body
weight, body mass index, and resting arterial systolic
and diastolic blood pressure. Mean height was signifi-
cantly lower and mean resting heart rate was signifi-
cantly higher in the NF1 than in the control group, andFigure 1 Automatic analysis screen of the computer software, showin
hyperemia index. HR: heart rate. Source: Itamar Medical Ltd. Software Versiomean body mass index was significantly higher for
women in the NF1 than in the control group (p < 0.05
each). Group characteristics are summarized in Table 1.
Blood test results were within normal ranges in all par-
ticipants (Table 2). Some mean values showed significant
between group differences, but these differences were
not clinically relevant.
The percentage of subjects with ED (RHI < 1.35) was
13.8% (4/29) in the NF1 group and 3.3% (1/30) in the
control group (p = 0.153). The RHI medians and inter-
quartile intervals were 1.8 (1.58-2.43) for the NF1 group
and 2.02 (1.74 – 2.49) for the control group (p = 0.361).
When the LnRHI means were compared using paramet-
ric tests, the difference was not statistically significant (p
= 0.224). Figure 2 shows the distribution of all results in
cases and controls as a scatter plot.
Discussion
To our knowledge, this study is the first to evaluate
endothelial function using PAT in NF1 patients. Con-
trary to expectations, these results suggest that the
endothelial function of young adults with NF1 does not
different from that of similar subjects without NF1.
Exacerbated vascular injury responses and chronic in-
flammation have been observed in murine models of
NF1, and chronic inflammation in patients with NF1,
suggesting that these factors could lead to ED [8]. Nei-
ther that study, nor studies on neurofibromin and endo-
thelium in mice [6] and humans [7] tested endothelial
function, although they did show that neurofibromin
was expressed in endothelial cells [7] and that
neurofibromin was important in cardiac embryogenesis
in mouse models [6].g test results in one participant. Abbreviations: RHI: reactive
n 3.2.4.







Age (years) 25 ± 4 24 ± 3 0.219
Women 23(79%) 21(70%) 0.412
Physically active 7(24%) 14(46%) 0.071
Weight of women (kg) 55 ± 9 56 ± 6 0.692
Weight of men (kg) 69 ± 8 73 ± 6 0.303
Stature of women (cm) 158 ± 6 164 ± 6 0.003
Stature of men (cm) 173 ± 5 179 ± 4 0.038
Body mass index of women (kg/m2) 22,0 ± 2,4 20,8 ± 1,5 0.046
Body mass index of men (kg/m2) 22,9 ± 2 22,7 ± 1,3 0.812
Systolic blood pressure (mmHg) 113 ± 9 114 ± 7 0.974
Diastolic blood pressure (mmHg) 72 ± 7 75 ± 8 0.300
Resting heart rate (bpm) 76 ± 7 69 ± 8 0.002
Data shown as means ± standard deviations or absolute count (percentage).
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portionate mortality ratio (PMR) for diseases of the cir-
culatory system in individuals with than without NF1,
especially for ischemic heart disease, which is closely re-
lated to atherosclerosis and endothelial dysfunction
[15,16]. Moreover, in a similar study [3], although theTable 2 Blood test results of the participants in the NF1
and control groups
Blood test NF1 Controls P
Total cholesterol – mg/dL 168 ± 35 182 ± 36 0.137
LDL cholesterol – mg/dL 99 ± 28 107 ± 30 0.309
HDL cholesterol – mg/dL 53 ± 12 58 ± 13 0.169
VLDL cholesterol – mg/dL 15 ± 7 17 ± 6 0.369
Triglycerides – mg/dL 78 ± 36 85 ± 34 0.452
Fasting glycaemia – mg/dL (70–99)* 83 ± 5 81 ± 5 0.169
Serum creatinine – mg/dL (0.4-1.3)* 0.66 ± 0.13 0.77 ± 0.14 0.005
Serum urea – mg/dL (15–40)* 27 ± 8 26 ± 7 0.768
AST - U/L (4 – 38)* 21 ± 6 26 ± 5 0.001
ALT - U/L (4 – 38)* 20 ± 19 20 ± 9 0.907
Serum total bilirubin – mg/dL
(up to 1.2)*
0.75 ± 0.52 0.75 ± 0.35 0.986
Direct bilirubin – mg/dL (up to 0.4)* 0.28 ± 0.10 0.30 ± 0.11 0.432
Indirect bilirubin – mg/dL 0.49 ± 0.48 0.45 ± 0.28 0.703
Prothrombin activity - % (70–100)* 84 ± 13 90 ± 7 0.034
TSH - mcIU/mL (0.44 – 4.48)* 1.77 ± 0.89 1.67 ± 0.76 0.649
Free T4 - ng/dL (0.8 – 1.9)* 1.29 ± 0.17 1.16 ± 0.16 0.006
Hemoglobin – g/dL (12–18)* 14.1 ± 1.2 14.4 ± 1.1 0.298
Hematocrit - % (35–52)* 41.5 ± 3.4 42.0 ± 2.9 0.499
WBC count -/mm3 (4,000-11,000)* 6,933 ± 1,924 5,798 ± 1,438 0.013
Platelet count -/mm3
(140,000-450,000)*
262,758 ± 61,586 250,620 ± 62,143 0.458
Data shown as means ± standard deviations.
* Normal reference range of the test.PMR for vascular diseases in general was found to be
higher in NF1 patients, the PMR for diseases of the ar-
teries and arterioles, including atherosclerosis, was
lower, a finding consistent with ours.
Our method of assessing endothelial function has sev-
eral limitations. However, another method, the brachial
artery reactivity test (BART), while being the most vali-
dated, requires extensive training and standardization.
This has led to the development of alternative methods
of evaluating endothelial function [17], including the
PAT used here. We chose this method because it is sim-
ple, non-operator-dependent and commercially available,
and because our research group has used it in patients
with other diseases and has found its results reprodu-
cible [18].
Moreover, PAT and BART do not measure the same
aspects of vascular biology. PAT measures the vasodila-
tor response of the digital microvasculature to ischemia,
whereas BART measures the response of the conduit ar-
teries. The vascular bed and vessel size likely determine
sensitivity to early damage from specific cardiovascular
risk factors [19,20]. Therefore, the stage of disease pro-
gression may affect the ability of different methods to
detect “abnormal” endothelial function. Nevertheless,
both the PAT and BART methods correlate well with
risk factors for CAD [15,19] and with coronary artery
endothelial function [12,21] and both are able to predict
future vascular events [16,22], although they correlate
modestly, if at all, with each other [19]. Therefore, each
method complements the other, providing additional in-
formation on endothelial function. BART likely provides
more important information on individuals with existing
atherosclerosis, whereas PAT may be an earlier indicator
of CAD risk. Thus, PAT seemed more appropriate for
profiling our study population.
Another concern about the PAT method was that the
cutoff value was based on findings of a receiver operat-
ing characteristics (ROC) curve, which found that a cut-
off value of 1.35 to diagnose patients with ED had a
sensitivity of 80% and a specificity of 85% [12]. This cut-
off value was based on patients referred for diagnostic
percutaneous coronary angiography, a high-risk popula-
tion with current or developing vascular disease. Thus,
using the same cutoff value on a population of young,
asymptomatic adults without vascular disease risk fac-
tors, as in our study, is questionable because it could
change the predictive value of the test, especially if used
for screening. We therefore used a combination of this
cutoff value and LnRHI, which allowed for a comparison
of mean values. Nevertheless, we found that the between
group difference in mean LnRHI values was not statisti-
cally significant.
Only a few studies have used EndoPAT to non-


























Figure 2 Scatter plot of reactive hyperemia index (RHI) values in both controls and patients with NF1.
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expected prevalence of ED in the control group. One
study tested the feasibility and reproducibility of
EndoPAT in adolescents but did not indicate the per-
centage of subjects that presented with ED [23]. Simi-
larly, a study that assessed ED in diabetic children [24]
did not indicate how many of them had ED, as defined
by the cutoff values. Since both studies compared mean
and standard deviations of RHI values between groups,
it was difficult to determine how many subjects in each
group were below the cutoff value. Moreover, when
establishing values in healthy control subjects, it should
be remembered that the results of non-invasive endothe-
lial function tests vary significantly in an individual on
different days; however, it is not clear if this is due to
physiologic oscillations in endothelial function or to the
imprecision of the methods [25].
Several characteristics differed significantly between our
NF1 and control groups, including height, body mass
index of women and resting heart rate, but, after adjust-
ment to account for these differences in the covariance
analysis, none was found to affect RHI (data not shown).
One of the relative limitations of this study is its sam-
ple size; the observed difference in the prevalence of ED
(10.5%) was lower than the difference expected (30%)
when calculating sample size, thus reducing its post hoc
power (30%). Although this sample was not powered to
exclude small differences between groups, our findings
suggest that ED is not clinically relevant in patients with
NF1. This lack of difference in endothelial function sug-
gests the need for further studies evaluating additional
markers of ED, markers that are more sensitive andspecific than PAT. In addition, older patients with NF1
should be included. These changes may result in a more
precise determination of the function of neurofibromin
in haploinsufficient endothelium.
Finally, understanding the natural history of NF1
vasculopathy requires prospective evaluations of the endo-
thelial response of NF1 patients to risk factors of vascular
disease. Our clinical observations suggested that athero-
sclerotic vascular disease risk factors, such as obesity, type
2 diabetes and hypertension, have lower prevalence in
NF1 patients than in healthy controls, although this find-
ing has not been confirmed. Thus, NF1 patients who die
at a younger age due to vascular disease may do so from
pathological mechanisms that may be different from those
in the general population. Vascular disease in patients with
NF1 may be caused by other factors, such as arterial
fibromuscular dysplasia, rather than atherosclerotic dis-
ease [26]. Furthermore, both death certificate studies
showed that patients with NF1 had a lower PMR for
atherosclerosis-related conditions, including ischemic
heart disease [4] and diseases of the arteries and arterioles
[3], and a much lower PMR for atherosclerosis risk factors,
such as diabetes [3,4] and hypertension [4].
These observations and our results are in agreement,
that ED is not more prevalent in patients with NF1 than
in the general population. Prospective assessment of vas-
cular disease and endothelial function in patients with
NF1 may provide greater understanding of this subject.
Conclusion
The prevalence of endothelial dysfunction was no higher
in NF1 patients than in healthy subjects.
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